Key statistics
As of last trade, Nuvectis Pharma Inc (NVCT:NAQ) traded at 6.63, 13.33% above the 52 week low of 5.85 set on Aug 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.71 |
---|---|
High | 6.86 |
Low | 6.54 |
Bid | 6.56 |
Offer | 6.70 |
Previous close | 6.75 |
Average volume | 87.83k |
---|---|
Shares outstanding | 18.65m |
Free float | 8.72m |
P/E (TTM) | -- |
Market cap | 125.91m USD |
EPS (TTM) | -1.29 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 18:31 BST.
More ▼
- Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
- Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
- Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
- Nuvectis Pharma to Present at the 36th Annual Roth Conference
- Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
- Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
- Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
- Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
More ▼